| アブストラクト | Leflunomide is indicated for the treatment of adults with rheumatoid arthritis, yet is underutilized. Given the cost of biologic therapy, understanding real-life effectiveness, safety, and sustainability of leflunomide, particularly in patients who have failed methotrexate, would be of value. The primary objective was to assess the proportion of patients achieving clinically meaningful benefit following an adequate trial of leflunomide. A retrospective analysis of a cohort supplemented with patient self-reported data using a standardized questionnaire. Data were analyzed using descriptive statistics, with a database multivariate logistic regression analysis to determine predictors of leflunomide response. Of the cohort available (N = 2591), 1671 patients with confirmed leflunomide use were included in the retrospective analysis, of whom 249 were incident users. Low disease activity (DAS-28 < 3.2) was achieved or maintained by 20% of incident users, with 19% achieving a clinical response (DAS-28 decrease >/=1.2) at 3 months. Adverse effects (AE) were reported by 29% of incident users and after 1 year, 45% remained on leflunomide. Achievement of "minimal or no joint symptoms" was reported by 34% in the 661 analyzable survey responses (39% response rate). AE were reported by 55%, with nuisance (hair loss, nausea, stomach pain) AE and diarrhea being most common. Leflunomide was discontinued by 67% of responders within 1 year. An important proportion of patients, the majority of whom had previously failed methotrexate, achieved disease response with leflunomide with a low risk of serious adverse effects, suggesting that a trial of leflunomide may be a reasonable and cost-effective strategy prior to biologic therapy. |
|---|
| ジャーナル名 | Clinical rheumatology |
|---|
| Pubmed追加日 | 2017/5/28 |
|---|
| 投稿者 | Schultz, Morgan; Keeling, Stephanie O; Katz, Steven J; Maksymowych, Walter P; Eurich, Dean T; Hall, Jill J |
|---|
| 組織名 | Misericordia Hospital, Covenant Health, 16940 87Ave, Edmonton, AB, T5R 4H5,;Canada.;Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta,;8-130K Clinical Sciences Building, 11350 83 Ave, Edmonton, AB, T5G 2G3, Canada.;School of Public Health, University of Alberta, 2-040 Li Ka Shing Centre for;Health Research Institute, Edmonton, AB, T6G 2E1, Canada.;Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, 3-171;Edmonton Clinic Health Academy, 11405-87Ave, Edmonton, Alberta, T6G 1C9, Canada.;Jill.Hall@ualberta.ca. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/28550389/ |
|---|
